Omarigliptin, also known as MK-3102, is a potent and long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. MK-3102 (omarigliptin), was identified as a potent and selective dipeptidyl peptidase 4 (DPP-4) inhibitor with an excellent pharmacokinetic profile amenable for once-weekly human dosing and selected as a clinical development candidate. Omarigliptin is currently in phase 3 clinical development.
DPP-4 Inhibitor Related Products:
Alogliptin benzoate; Sitagliptin phosphate monohydrate; Linagliptin; Vildagliptin; Saxagliptin; Trelagliptin succinate; Teneligliptin hydrobromide; Saxagliptin hydrate; Trelagliptin; Saxagliptin HCL; Alogliptin